1 Result(s)

Article

Evaluating results from the multiple myeloma patient subset treated with denosumab or zoledronic acid in a randomized phase 3 trial

In a phase 3 trial of denosumab vs zoledronic acid in patients (n=1776) with bone metastases and solid tumors or multiple myeloma, denosumab was superior to zoledronic acid for the primary end point of prevention...

N Raje, S Vadhan-Raj, W Willenbacher, E Terpos, V Hungria… in Blood Cancer Journal (2016)